迈得医疗(688310) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 was ¥54,179,451, a decrease of 59.03% compared to the same period last year[2]. - The net profit attributable to shareholders was -¥2,250,020.31, reflecting a decline of 107.06% year-over-year[2]. - The net profit after deducting non-recurring gains and losses was -¥6,781,418.77, a decrease of 123.04% compared to the previous year[2]. - The company's operating revenue for the year-to-date period decreased by 33.45% due to fluctuations in downstream market demand and reduced customer investment willingness[8]. - The net profit attributable to shareholders for the year-to-date period declined by 107.06 million, primarily due to the decrease in operating revenue and increased competitive pressure in certain product markets[8]. - The basic earnings per share for the current reporting period was -103.70 yuan, a decrease attributed to the decline in net profit attributable to shareholders[8]. - The weighted average return on equity for the current reporting period was -107.12%, indicating a significant drop in profitability[8]. - Total operating revenue for the first three quarters of 2024 was CNY 219,574,032.71, a decrease of 33.5% compared to CNY 329,920,089.50 in the same period of 2023[19]. - Net profit for the first three quarters of 2024 was CNY 2,032,527.91, a significant decline of 97.5% compared to CNY 81,881,942.77 in 2023[20]. - The company recorded a total profit of CNY 4,603,951.64 for the first three quarters of 2024, down from CNY 96,713,998.55 in 2023, representing a decline of 95.2%[20]. - The company’s total comprehensive income for the first three quarters of 2024 was CNY 2,051,864.39, a decrease from CNY 81,731,356.05 in 2023[21]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,051,060,311.70, down 8.59% from the previous year[3]. - The company's equity attributable to shareholders decreased by 5.88% to ¥841,299,242.86 compared to the end of the previous year[3]. - The total current assets decreased from RMB 720,324,715.93 as of December 31, 2023, to RMB 602,438,110.92 as of September 30, 2024, representing a decline of approximately 16.4%[16]. - The company's cash and cash equivalents decreased from RMB 289,017,702.36 to RMB 81,021,108.35, a drop of about 72%[15]. - The total liabilities decreased from RMB 209,601,710.61 to RMB 170,678,721.37, a reduction of about 18.6%[17]. - The total equity attributable to shareholders decreased from RMB 893,842,295.53 to RMB 841,299,242.86, a decline of approximately 5.9%[18]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥42,692,881.32, down 48.99% year-over-year[2]. - The net cash flow from operating activities for the year-to-date period decreased by 48.99 million, primarily due to a decline in cash received from sales and services[8]. - Cash inflow from operating activities for the first three quarters of 2024 was CNY 376,773,166.91, compared to CNY 430,501,605.78 in 2023, indicating a decrease of 12.5%[22]. - The net cash flow from investing activities was -175,620,736.73, compared to -30,693,355.83 in the previous period, indicating a significant increase in cash outflow[23]. - The total cash outflow from financing activities was 59,494,178.91, up from 41,347,714.87 in the previous period, reflecting increased financial obligations[24]. - The net increase in cash and cash equivalents was -191,980,905.53, contrasting with a positive increase of 39,698,309.64 in the previous period[24]. - The ending balance of cash and cash equivalents was 74,689,718.30, down from 261,550,176.95 in the previous period, indicating a substantial decrease in liquidity[24]. Research and Development - Research and development expenses totaled ¥8,558,667.14, a decrease of 30.89% year-over-year, accounting for 15.80% of operating revenue, an increase of 6.44 percentage points[3]. - Research and development expenses for the current reporting period amounted to 30.89 million, with R&D expenses accounting for 68.80% of operating revenue, reflecting a significant increase due to the decline in revenue[8]. - Research and development expenses for the first three quarters of 2024 were CNY 28,854,806.83, an increase of 8.1% from CNY 26,700,469.34 in 2023[19]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 4,462, with the top ten shareholders holding a significant portion of shares[10]. - The largest shareholder, Lin Junhua, holds 47.42% of the shares, amounting to 78,372,560 shares[10]. - The company plans to repurchase shares with a total amount not less than 15 million yuan and not exceeding 30 million yuan, with a repurchase price capped at 15 yuan per share[13]. - As of September 30, 2024, the company has repurchased a total of 457,144 shares, accounting for 0.2766% of the total share capital of 165,269,766 shares, with a total expenditure of RMB 4,296,367.13[14]. Market Conditions - The company attributed the decline in operating revenue to fluctuations in downstream market demand and increased competitive pressure in certain product markets[6]. - The company continues to invest in market expansion and improving customer service satisfaction despite the financial challenges faced[8].